COVID-19 and prevalence of venous thromboembolism among cancer patients: A nationwide inpatient sample analysis.

• DOI: 10.1200/jco.2023.41.16_suppl.e18839
• Publication Date: 2023-06-04T16:03:39Z
• Authors: Muhammad Bilal Ib...; Rafaella Litvin; Hiba Noor; Ali Husnain Khan; Michelle Ishaya; Khaldun Obeidat; Philip Onyekaoso ...; Ayobami Gbenga Ol...; Ekrem Turk; Badri Aryal; Muhammad Tayyab A...; Aneeza Jamshed; Kunnal Batra
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e18839 Background: Cancer, as well immunosuppression from chemotherapy, aggravates thromboembolism risk. The risk is likely amplified in an additive fashion with COVID-19 infection, which confers a higher of VTE viral sepsis, endothelial inflammation, and microthrombi formation. Numerous studies have shown the heightened pulmonary embolism among severe patients. We sought to evaluate further extent COVID-19-associated coagulopathy associated outcomes. Methods: National Inpatient Sample 2020 was used identify non-elective hospitalizations patients secondary diagnosis any cancer. These were stratified into two cohorts based on presence primary COVID-19. Primary outcomes include venous thromboembolism, PE, without PE cancer Covid-19 infection. examined in-patient mortality, average length stay (LOS), total hospital charge (THC). Multivariate analysis performed obtain odds ratio. All weighted conducted through STATA 17. Results: Out 1,734,735 admissions cancer, 36,295 (2%) admitted for Our showed statistically non-significant increased thromboembolism(aOR:1.09 CI 0.99-1.20) COVID. There was, however, significant increase embolism(aOR 1.7, CI: 1.51- 1.91) Covid-19. decreased PE(aOR: 0.67 0.57-0.78). mortality (aOR: 2.8 2.63-3.0), stay(aOR:1.85 1.65- 2.05), charges($83,201 vs. $78,869 p: < 0.01) compared Conclusions: This study shows that has deleterious effects, including poor in-hospital finding lower incidence non-PE related limitations coding NIS, complexity codes might be omitted multiple diagnoses. With significantly economic burden, these findings emphasize significance thrombotic prophylaxis vaccination [Table: see text]